{"id":18417,"date":"2021-07-08T12:06:51","date_gmt":"2021-07-08T10:06:51","guid":{"rendered":"https:\/\/idibell.cat\/?p=18417"},"modified":"2021-07-08T12:07:16","modified_gmt":"2021-07-08T10:07:16","slug":"limpacte-de-lobesitat-es-cada-vegada-mes-determinant-en-el-trasplantament-renal","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/07\/limpacte-de-lobesitat-es-cada-vegada-mes-determinant-en-el-trasplantament-renal\/","title":{"rendered":"L\u2019impacte de l\u2019obesitat \u00e9s cada vegada m\u00e9s determinant en el trasplantament renal"},"content":{"rendered":"
En el darrer mig segle l\u2019obesitat ha crescut entre un 5% i un 10% en la poblaci\u00f3 masculina i entre un 8% un 14% entre la femenina. Segons diferents estimacions m\u00e9s de 650 milions de persones tenen problemes d\u2019obesitat<\/strong>. Aquest augment de la prevalen\u00e7a de l\u2019obesitat s\u2019ha reflectit tamb\u00e9 en els donants i receptors de trasplantament renal. El grup de recerca en Nefrologia i Trasplantament Renal<\/a> de l\u2019IDIBELL i l\u2019Hospital Universitari de Bellvitge (HUB) ha publicat un estudi a la revista Nephron<\/em><\/a> que revisa els darrers treballs publicats sobre el creixent impacte de l\u2019obesitat en les diferents etapes i actors implicats en el transplantament renal.<\/p>\n Una de les principals conclusions de la revisi\u00f3 que han dut a terme els nefr\u00f2legs de l\u2019IDIBELL i l\u2019Hospital de Bellvitge \u00e9s que la p\u00e8rdua de pes \u00e9s un requeriment que ha de d\u2019esdevenir molt m\u00e9s rellevant com a pas previ al trasplantament<\/strong>. En aquest sentit, subratllen la necessitat d\u2019incloure de forma m\u00e9s expl\u00edcita a les guies cl\u00edniques de trasplantament, i com a campanya de sensibilitzaci\u00f3 entre els candidats, la rellev\u00e0ncia de la p\u00e8rdua de pes pr\u00e8via, juntament amb l\u2019exercici f\u00edsic i una dieta saludable. \u201cEl trasplantament \u00e9s el tractament que aporta m\u00e9s qualitat de vida a les persones amb una malaltia renal cr\u00f2nica greu i estudis recents mostren que perdre pes una vegada rebut el rony\u00f3 no comporta millores significatives en la superviv\u00e8ncia de l\u2019empelt<\/em>\u201d, explica la Dra. Maria Quero, investigadora de l\u2019IDIBELL i l\u2019HUB.<\/p>\n Els pacients que reben hemodi\u00e0lisi es troben amb un fenomen d\u2019epidemiologia inversa: l\u2019obesitat i d\u2019altres factors de risc cardiovascular tenen una certa funci\u00f3 de protecci\u00f3 envers la seva malaltia renal. Tot i aix\u00f2, el trasplantament renal \u00e9s el millor tractament possible a llarg termini, segons s\u2019evidencia als treballs previs que s\u2019han revisat per a l\u2019estudi.<\/p>\n L\u2019obesitat apareix com un dels criteris de valoraci\u00f3 per als pacients candidats a rebre un trasplantament renal. \u00c9s un factor de risc cardiovascular i d\u2019altres trastorns del metabolisme molt important. El trasplantament renal augmenta la superviv\u00e8ncia dels pacients de malalties renals cr\u00f2niques<\/strong>, per\u00f2 tot i aix\u00ed un 17% de les morts de receptors d\u2019un trasplantament renal es deu a una malaltia cardiovascular.<\/p>\n Un \u00edndex de massa corporal (IMC) a partir de 30-35 pot suposar que una persona amb malaltia renal cr\u00f2nica estigui m\u00e9s temps a la llista d\u2019espera o que no pugui afegir-se a la mateixa si arriba a nivells d\u2019obesitat m\u00f2rbida. Tot i que l\u2019obesitat s\u2019associa amb complicacions en el trasplantament renal, diferents estudis analitzats en el treball permeten concloure que el trasplantament tamb\u00e9 millora la superviv\u00e8ncia dels pacients obesos amb malalties renals cr\u00f2niques. En aquest sentit, l\u2019estudi de l\u2019IDIBELL i l\u2019Hospital de Bellvitge subratlla la conveni\u00e8ncia de no utilitzar l\u2019IMC com a criteri \u00fanic de classificaci\u00f3 dels pacients a les llistes d\u2019espera. En comptes d\u2019aix\u00f2, proposa analitzar cada cas de forma individual i tenir en compte altres factors que poden explicar l\u2019augment de pes, com ara l\u2019acumulaci\u00f3 de l\u00edquids o la distribuci\u00f3 de la massa muscular.<\/p>\n <\/p>\n <\/p>\n L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":" Un estudi del grup de recerca en Nefrologia i Trasplantament Renal de l\u2019IDIBELL i l\u2019Hospital Universitari de Bellvitge destaca la necessitat de conscienciar m\u00e9s i millor tant a candidats al trasplantament com a possibles donants<\/p>\n","protected":false},"author":8,"featured_media":18418,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[334,339,479],"tags":[],"class_list":["post-18417","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-translacional","category-nefrologia-i-transplantament-renal","category-p-de-malalties-infeccioses-i-transplantaments"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 02:55:57","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=18417"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/18417\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/18418"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=18417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=18417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=18417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}